Current issues regarding beta-adrenergic blockade in patients with congestive heart failure: Patient selection, nonselective versus selective blockade, management of adverse effects, and indications for withdrawal of therapy

Current Cardiology Reports

Volumn 1, Issue 1, 1999, Pages 47-54

  Moskowitz, Robert ^a   Kukin, Marrick ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CHEMICALLY INDUCED DISORDER; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; HUMAN; MORTALITY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SURVIVAL; WITHDRAWAL SYNDROME;

ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE, CONGESTIVE; HUMANS; HYPOTENSION, ORTHOSTATIC; PROGNOSIS; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SUBSTANCE WITHDRAWAL SYNDROME; SURVIVAL ANALYSIS;

EID: 0033123119     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0042-8     Document Type: Article

References (65)

1. Packer M: The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
2. Bristow MR: Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993, 71:12C-22C.
3. Packer M, Lee WH, Kessler PD, et al.: Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987, 75 (suppl IV):80-92.
4. Chidsey CA, Harrison DC, Braunwald E, et al.: Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962, 267:650-654.
5. Thomas JA, Marks BH: Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978, 41: 233.
6. Singal PK, Kapur N, Dhillon KS, et al.: Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 1982, 60:1390-1397.
7. Haggendal J, Jonsson L, Johansson G, et al.: Catecholamine-induced free radicals in myocardial cell necrosis on experimental stress in pigs. Acta Physiol Scand 1987, 131:447-452.
8. Bristow M, Port JD: β adrenergic blockade in chronic heart failure. Scandinavian Cardiovascular Journal 1998, 32 (suppl 47):45-55.
9. Waagstein F, Hjalmarson A, Varnauskas E, et al.: Effect of chronic beta adrenergic receptor blockade in congestive car diomyopathy. Br Heart J 1975, 37:1022-1036.
10. The MDC Trial Study Group: Metoprolol in dilated cardiomyopathy: Multicenter randomized placebo controlled trial. Lancet 1993, 342:1441-1446.
11. Bristow MR, Gilbert EM, Abraham WT, et al. for the MOCHA Investigators: Carvedilol produces dose related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807-2816.
12. Kukin ML, Kalman J, Mannino MM, et al.: A direct comparison of metoprolol and carvedilol in CHF [abstract]. Circulation 1997, 96 (suppl I):I 577.
13. Olsen SL, Gilbert EM, Renlund DG, et al.: Carvedilol improves left ventricular function and symptoms in chronic heart fail ure: A double blind randomized study. J Am Coll Cardiol 1995, 25:1225-1231.
14. Bristow MR, O'Connell JB, Gilbert EM, et al. for the Bucindolol Investigators: Dose response of chronic b-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994, 89:1632-1642.
15. Australia/New Zealand Heart Failure Research Collaborative Group: Randomised, placebo controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997, 349:375-380.
16. Gilbert EM, Anderson JL, Deitchman D, et al.: Chronic β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double blind, random ized study of bucindolol versus placebo. Am J Med 1990, 88:223-229.
17. CIBIS Investigators and Committees: A randomized trial of beta blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study. Circulation 1994, 90:1765-1773.
18. Packer M, Colucci WS, Sackner-Bernstein JD, et al. for the PRECISE Study Group: Double blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996, 94:2793-2799.
19. Colucci WS, Packer M, Bristow MR, et al. for the U.S. Carvedilol Heart Failure Study Group: Carvedilol inhibits clinical pro gression in patients with mild symptoms of heart failure. Circulation 1996, 94:2800-2806.
20. Lowes BD, Gill EA, Rodriguez-Larrain J, et al: Carvedilol is associated with a reversal of remodeling in chronic heart fail ure [abstract]. Circulation 1996, 94 (suppl I):I-407.
21. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
22. Doughty RN, Rodgers A, Sharpe N, et al.: Effects of beta-blocker therapy on mortality in patients with heart failure: A systematic overview of randomized controlled trials. European Heart Journal 1997, 18:560-565.
23. Heidenreich PA, Lee TT, Massie BM: Effect of beta-blockade on mortality in patients with heart failure: A meta analysis of randomized clinical trials. J Am Coll Cardiol 1997, 30:27-34.
24. CIBIS II Investigators: The cardiac insufficiency bisoprolol study II: a randomised trial. Lancet 1999, 353:9-13.
25. Goldstein S, Hjalmarson A: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT HF). Circulation 1998, 98(suppl):I 364.
26. Packer M: Effects of beta adrenergic blockade on survival of patients with chronic heart failure. Am J Cardiol 1997, 80 (suppl 11A):46L-54L.
27. Cohn JN, Fowler MB, Bristow MR, et al.: Safety and efficacy of carvedilol in severe heart failure: The U.S. Carvedilol Heart Failure Study Group. Journal of Cardiac Failure 1997, 3:173-179.
28. Goldstein S: Clinical studies on beta blockers and heart fail ure preceding the MERIT HF Trial: Metoprolol CR/XL Ran domized Intervention Trial in Heart Failure. Am J Cardiol 1997, 80 (suppl 9B):50J-53J.
29. Haber HL, Simek CL, Gimple LW, et al.: Why do patients with congestive heart failure tolerate the initiation of β blocker therapy? Circulation 1993, 88:1610-1619.
30. Kukin ML, Kalman J, Mannino MM, et al.: β blockade in congestive heart failure: Persistent adverse haemodynamic effects during chronic treatment with subsequent doses. Heart 1997, 78:444-449.
31. Sackner-Bernstein J, Krum H, Goldsmith RL, et al.: Should worsening heart failure early after initiation of beta blocker therapy for chronic heart failure preclude long term treat ment [abstract]? Circulation 1995, 92 (suppl I):I-395.
32. Pfeffer MA, Braunwald E, Moye LA, et al. on behalf of the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlarge ment Trial. N Engl J Med 1992, 327:669-677.
33. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
34. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
35. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
36. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
37. Eichhorn EJ, Lukas MA, Shusterman N: Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity [abstract]. Circulation 1998, 98 (suppl I):I-365.
38. Constant J: A review of why and how we may use beta block ers in congestive heart failure. Chest 1998, 113:800-808.
39. Yamada T, Fukunami M, Ohmori M, et al.: Which subgroup of patients with dilated cardiomyopathy would benefit from long term beta blocker therapy: A histologic viewpoint. J Am Coll Cardiol 1993, 21:628-633.
40. Yamada T, Abe Y, Fukunami M, et al.: Could effectiveness of long term b-blocker therapy for dilated cardiomyopathy be predicted by signal averaged electrocardiography [abstract]? Circulation 1995, 92 (suppl I):I-73.
41. Suwa M, Takahide I, Yoshiaki O, et al.: Myocardial integrated ultrasonic backscatter in patients with dilated cardiomyopathy: Prediction of response to beta-blocker therapy [abstract]. Circulation 1998, 98 (suppl I):I-365.
42. Krum H: Beta-adrenoreceptor blockers in chronic heart failure: A review. Br J Clin Pharmacol 1997, 44:111-118.
43. Bristow MR, Hershberger RE, Port JD, et al.: b-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990, 82 (suppl I):12-25.
44. Gilbert EM, Abraham WT, Olsen S, et al.: Comparative hemodynamic, LV functional, and anti-adrenergic effects of chronic treatment with metoprolol vs carvedilol in the failing heart. Circulation 1996, 94:2817-2825.
45. Newton GE, Parker JD: Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996, 94:353-358.
46. McMurray J, McLay J, Chopra M, et al.: Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990, 65:1261-1262.
47. Belch JJF, Bridges AB, Scott N, et al.: Oxygen free radicals and congestive heart failure. Br Heart J 1991, 65:245-248.
48. Sobotka PA, Brottman MD, Weitz Z, et al.: Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic Biol Med 1993, 14:643-647.
49. McMurray J, Chopra M, Abdullah I, et al.: Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993, 14:1493-1498.
50. Moskowitz R, Kukin M: Oxidative stress and congestive heart failure. Congestive Heart Failure, in press.
51. Yue T, Cheng H, Lysko PG, et al.: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992, 263:92-98.
52. Feuerstein GZ, Yue T, Cheng H, et al.: Myocardial protection by the novel vasodilating beta-blocker, carvedilol: Potential relevance of anti-oxidant activity. J Hypertens 1993, 11: S41-S48.
53. Kukin ML, Kalman J, Mannino MM, et al.: Antioxidant effect of carvedilol and metoprolol in congestive heart failure [abstract]. J Am Coll Cardiol 1998, 31 (suppl):189A.
54. Lechat P, Packer M, Chalon S, et al.: Clinical effects of b-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled randomized trials. Circulation 1998, 98:1184-1191.
55. Bristow MR, Larrabee P, Minobe W, et al.: Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992, 19 (suppl I):S68-S80.
56. Hershberger RE, Wynn JR, Sundberg L, et al.: Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990, 15:959-967.
57. Eichhorn EJ: Effects of bucindolol in heart failure. Am J Cardiol 1993, 71:1C-6C.
58. Eichhorn EJ: Restoring function in failing hearts: The effects of beta blockers. Am J Med 1998, 104:163-169.
59. Eichhorn EJ, Bristow MR: Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997, 79:794-798.
60. Talwar KK, Bhargava B, Upasani PT, et al.: Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. Journal of Cardiac Failure 1996, 2:273-277.
61. Kukin ML, Kalman J, Mannino M, et al.: Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Am J Cardiol 1996, 77:486-491.
62. DiLenarda A, Salvatore L, Gregori D, et al.: Effects of carvedilol on left ventricular function and remodeling in patients with dilated cardiomyopathy with persistent left ventricular dysfunction despite optimal conventional therapy [abstract]. J Am Coll Cardiol 1998, 31 (suppl):A189.
63. Kukin M: Carvedilol. Comprehensive Therapeutics 1997, 23:617-620.
64. Tsvetkova TO, Farber DJ, Abraham WT, et al.: Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol [abstract]. Journal of Cardiac Failure 1998, 4 (suppl 1):36.
65. Packer M, Cohn JN on behalf of the steering committee and membership of the advisory council to improve outcomes nationwide in heart failure: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999, 83(suppl 2A):17A-22A.